Kyowa Kirin Co., Ltd. (FRA:KY4)

Market Cap	7.72B
Revenue (ttm)	3.06B
Net Income (ttm)	317.60M
Shares Out	n/a
EPS (ttm)	0.60
PE Ratio	24.31
Forward PE	n/a
Dividend	0.35 (2.43%)
Ex-Dividend Date	Dec 27, 2024

Volume	50
Average Volume	30
Open	13.60
Previous Close	13.60
Day's Range	13.60 - 14.20
52-Week Range	12.30 - 20.60
Beta	n/a
RSI	67.83
Earnings Date	Jul 31, 2025

About Kyowa Kirin

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormon...

• Industry: Pharmaceutical Preparations
• Founded: 1949
• Employees: 5,669
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: KY4

Financial Performance

In 2024, Kyowa Kirin's revenue was 495.56 billion, an increase of 12.06% compared to the previous year's 442.23 billion. Earnings were 59.87 billion, a decrease of -26.26%.

Financial numbers in JPY